Tirzepatide is an injectable medication approved by the FDA for the treatment of type 2 diabetes and for chronic weight management in adults. It was first approved in 2022 under the brand name Mounjaro to improve glucose control in adults with type 2 diabetes, and in 2023, another version—Zepbound—was approved specifically for chronic weight management.
Tirzepatide is a prescription medication with formal regulatory approval, backed by Phase 3 clinical studies involving thousands of patients.
Tirzepatide works by simultaneously activating two incretin hormone receptors: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both hormones are involved in regulating appetite, metabolism, insulin secretion, blood glucose control, and energy balance.
In practical terms, this means the medication reduces hunger and increases the feeling of fullness by stimulating hunger-related brain centers and slowing gastric emptying—an effect commonly described as a reduction in "food noise," or the constant thoughts about eating.
It has demonstrated an unusually substantial degree of body weight reduction compared with other anti-obesity medications evaluated in phase 3 clinical trials.
In head-to-head studies, tirzepatide achieved greater weight loss than semaglutide in people with obesity, both with and without diabetes.
In addition to promoting weight loss and improving glucose control, it has been shown to reduce the risk of cardiovascular and diabetes-related events in patients with obesity.
Achieving and maintaining sustained weight loss of more than 10% of total body weight can reduce the risk of serious obesity-related complications and improve quality of life.
Results are achieved progressively, typically through gradual dose titration over several weeks to minimize gastrointestinal side effects.
An important point to convey is that patients often experience significant weight regain after discontinuing treatment; therefore, this constitutes the management of a chronic condition rather than a one-time treatment.
Backed by large-scale studies: the SURMOUNT clinical trial program included more than 5,000 individuals with obesity or overweight across six registration studies, consistently demonstrating significant body weight reduction compared to placebo.
It has been shown that, in addition to weight loss, it reduces the risk of cardiovascular and diabetes-related events, reinforcing its favorable benefit-risk profile for the indicated population.
